Sandoz, Momenta And Amphastar Settle US Enoxaparin Litigation
Executive Summary
Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.
You may also be interested in...
Momenta Shelves Adalimumab But Persists With Aflibercept
Having failed to find a commercial partner, Momenta has halted development on its adalimumab biosimilar. But it is continuing to work on biosimilar aflibercept in conjunction with partner Mylan.
Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement
The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
Amphastar Poised To Receive $59.9m In Momenta/Sandoz Settlement
The small generic drug company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.